Published online Sep 26, 2023. doi: 10.4252/wjsc.v15.i9.908
Peer-review started: May 12, 2023
First decision: June 29, 2023
Revised: July 23, 2023
Accepted: September 6, 2023
Article in press: September 6, 2023
Published online: September 26, 2023
Acute lung injury (ALI) has high morbidity and mortality rates and needs effective treatment. Research has found that the gut microbiota improves lung injury through the lung-gut axis. Human umbilical cord mesenchymal cells (HUC-MSCs) can improve ALI.
Although HUC-MSCs can improve ALI, their biological mechanism of action is not yet clear.
To explore changes in the microbiota in the lung-gut axis and the relationship with HUC-MSC treatment.
C57BL/6 mice were used to establish an ALI animal model by intraperitoneal injections of lipopolysaccharide. Wright’s staining, ELISA, hematoxylin-eosin staining, Evans blue dye leakage assay, immunohistochemistry, fluorescence in situ hybridization, and western blot were used to observe the improvement of ALI mice by HUC-MSCs. High-throughput 16S rDNA sequencing was used to observe the microbiota homeostases in the lung-gut axis. The non-targeted metabolomics was used to explore changes in lung tissue metabolites.
HUC-MSCs ameliorated histopathological damage in the lung and ileum of ALI mice. HUC-MSC treatment improved inflammation, endothelial barrier integrity, and bacterial translocation in the lungs and ileum of ALI mice. HUC-MSCs regulated lung-gut microbiota homeostasis. HUC-MSC treatment regulated the metabolic profile in the lung and ileum of ALI mice.
This study shows the improvement of changes in the lung and ileum of ALI mice by HUC-MSCs, and suggests a correlation between HUM-MSC-improved ALI and gut and lung microbiota homeostases.
This study explores the biological mechanism of HUC-MSCs in improving ALI from the perspective of the correlation between the microbiota in the lung-gut axis and lung tissue metabolites, providing a research basis for HUC-MSC treatment.